Please assess the completion status of the following clinical trial:

Trial Title: Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria of TB (tuberculosis ) subjects:~* Diagnosis TB ;~* 18 to 65 years ;~* Consent and signed informed consent forms(ICF) ;~* Comply with follow-up .~Exclusion Criteria of TB (tuberculosis ) subjects:~* advanced cancer, diabetes,copd in acute episodes, acute/ progressive liver disease or kidney disease, congestive heart failure, etc ;~* Taking part in other clinical or within 3 months involved in any other clinical;~* histories of allergy ;~* in pregnancy or lactation;~* In a mental illness ;~* Any conditions affect the trial evaluation.~Inclusion Criteria of Non-tuberculosis subjects with lung disease :~* Diagnosis non-tuberculosis subjects with lung disease ;~* 18 to 65 years ;~* Consent and signed signed informed consent forms(ICF) ;~* Comply with follow-up .~Exclusion Criteria of Non-tuberculosis subjects with lung disease :~* advanced cancer, diabetes,copd in acute episodes, acute/ progressive liver disease or kidney disease, congestive heart failure, etc ;~* Taking part in other clinical or within 3 months involved in any other clinical;~* histories of allergy;~* in pregnancy or lactation;~* In a mental illness ;~* Any conditions may affect the trial evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TB subjects (Type: EXPERIMENTAL): 96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
- non-TB subjects with lung disease (Type: ACTIVE_COMPARATOR): 96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).